MGC Pharmaceuticals has begun a pilot study assessing the influence of ArtemiC Support on patients with long-COVID Syndrome.
ArtemiC Support is the second product in MGC Pharma’s ArtemiC product range to progress to the clinical trial phase to determine their safety and efficacy against COVID-19 related diseases.
In 2020 MGC Pharma undertook a Phase II clinical trial for ArtemiC – which contains frankincense, curcumin and vitamin C – to determine its safety and efficacy in patients diagnosed with moderate COVID-19, and to evaluate their recovery rates. The study showed positive results – including faster clinical improvement and the ability to reduce symptoms and pain associated with COVID-19.
The initial ArtemiC Support pilot study is being carried out with partners Swiss PharmaCan AG and Glow LifeTech Ltd following Ethics Committee approval from Spanish research foundation, IDIAP Jordi Gol, on 9 December 2021.
Read more: MGC Pharma receives approval for COVID-19 treatment
MGC Pharma co-founder and managing director, Roby Zomer, commented: “This study is a crucial first step in determining whether ArtemiC Support helps long-COVID sufferers by treating what is often are very debilitating conditions.
“Working with our partners Swiss PharmaCan and Glow LifeTech, we are hopeful that this study will demonstrate that ArtemiC Support is as successful at helping patients with Long COVID, as the Phase II study undertaken in 2020 indicated that ArtemiC was in treating patients with moderate COVID-19.
“We look forward to publishing the results as soon as practicable, and hopefully extending the use of ArtemiC Support to a new group of patients.”
The study will be enrolling 150 patients suffering from post-acute COVID syndrome, with 50 already enrolled, and is expected to be completed by February 2022.
Under the parameters of the trial, patient participants will take ArtemiC Support for six weeks under supervision of their doctor, with their progress measured against a post-COVID Functional Scale (PCFS), and a 10-point Likert scale, one, two, three and six weeks after treatment commences.
The symptoms measured include: shortness of breath; abnormal physical weakness or lack of energy; loss of senses of smell; loss of sense of taste; cough; headache; and, mental confusion.
The study aims to initially obtain partial results on the effectiveness and safety in improving the functional status and symptomatology in patients suffering from the condition, and a further randomised, double-blind, placebo-controlled study is expected to follow for full information on efficacy and safety.
Swiss PharmaCan’s responsible person for this study, Dr Dieter Russman, commented: “In October 2021 Swiss PharmaCan gave the green light for a clinical study on the influence of ArtemiC Support in patients with Long COVID.
“I’m expecting highly valuable results on the safety and efficacy of ArtemiC Support, based on its breakthrough MyCell technology, and the potential benefit for millions of people suffering from long-COVID, who to date, have had limited therapeutic options available to them.”
[activecampaign form=31]
